News Column

New Cancer Therapy Findings Has Been Reported by Investigators at ICCOM (In vivo anticancer evaluation of the hyperthermic efficacy of anti-human...

August 6, 2014



New Cancer Therapy Findings Has Been Reported by Investigators at ICCOM (In vivo anticancer evaluation of the hyperthermic efficacy of anti-human epidermal growth factor receptor-targeted PEG-based nanocarrier containing magnetic nanoparticles)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news originating from Florence, Italy, by NewsRx correspondents, research stated, "Polymeric nanoparticles with targeting moieties containing magnetic nanoparticles as theranostic agents have considerable potential for the treatment of cancer. Here we report the chemical synthesis and characterization of a poly(D, L-lactide-co-glycolide)-b-poly(ethylene glycol)-based nanocarrier containing iron oxide nanoparticles and human epithelial growth factor receptor on the outer shell."

Our news journalists obtained a quote from the research from ICCOM, "The nanocarrier was also radiolabeled with Tc-99m and tested as a theranostic nanomedicine, ie, it was investigated for both its diagnostic ability in vivo and its therapeutic hyperthermic effects in a standard A431 human tumor cell line. Following radiolabeling with Tc-99m, the biodistribution and therapeutic hyperthermic effects of the nanosystem were studied noninvasively in vivo in tumor-bearing mice."

According to the news editors, the research concluded: "A substantial decrease in tumor size correlated with an increase in both nanoparticle concentration and local temperature was achieved, confirming the possibility of using this multifunctional nanosystem as a therapeutic tool for epidermoid carcinoma."

For more information on this research see: In vivo anticancer evaluation of the hyperthermic efficacy of anti-human epidermal growth factor receptor-targeted PEG-based nanocarrier containing magnetic nanoparticles. International Journal of Nanomedicine, 2014;9():3037-3056. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Oncology).

The news correspondents report that additional information may be obtained from G. Baldi, ICCOM CNR, Florence, Italy. Additional authors for this research include C. Ravagli, F. Mazzantini, G. Loudos, J. Adan, M. Masa, D. Psimadas, E.A. Fragogeorgi, E. Locatelli, C. Innocenti, C. Sangregorio and M.C. Franchini.

Keywords for this news article include: Italy, Europe, Florence, Oncology, Nanoparticle, Therapeutics, Nanotechnology, Membrane Proteins, Peptide Receptors, Emerging Technologies, Growth Factor Receptors

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters